TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04472988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing
Description: The first session will be assigned to the assessment and the exploration of the personal history and for presenting the method to the client. Then, each case will be conceptualized according to the Model of Two Method Approach and the protocol for the treatment will be used. The procedure will be organized around targeting the most ten disturbing memories which happened before the illness debut, including stressful or traumatic memories from childhood. The rationale behind this approach is that adverse events leave traces in the neural network of an individual in such a way that these cause a variety of emotional or cognitive symptoms. If we consider the illness as being also a symptom of a traumatic past, then we expect that by accessing the dysfunctionally stored memory and stimulating the innate processing system, the symptoms of the illness diminish.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants randomised in this group will receive a protocol focused only on present and future (present symptoms, daily problems, future projects). The psychologist will lead the discussion anywhere except for the past.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
Study: NCT02244268

Intervention type: DRUG
Intervention: ALNA®
Study: NCT02767518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
Study: NCT03974789

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Plasma cortisol level test

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour Urine test
Description: Urinary free cortisol test

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva swab
Description: salivette® for salivary cortisol quantification

Intervention type: DIAGNOSTIC_TEST
Intervention: Dexamethasone test
Description: Dectancyl® 2 x 0.5 mg tablets (total 1 mg)
Study: NCT04545476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Participants in this group will receive the experimental APIS Biomaterial on the Head.
Description: One layer of APIS® will be applied to the post-operative wound on the head covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Participants in this group will receive the experimental APIS Biomaterial on the Lower Extremities.
Description: One layer of APIS® will be applied to the post-operative wound on the lower extremities covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Secondary Intention Healing on the Head
Description: Participants in this group will receive standard secondary intention wound healing post-operative care on the Head. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Secondary Intention Healing on the Lower Extremities
Description: Participants in this group will receive standard secondary intention wound healing post-operative care on the Lower Extremities. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
Study: NCT02222337

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nueva Vida Intervention
Description: The psycho-educational format of the Nueva Vida Intervention is led by trained interventionists who have the survivors and caregivers go into different rooms to discuss the same topic. This format will allows them each to express their thoughts and feelings without inhibitions or concerns over how their survivor or their caregiver might respond. The specific topics for each wave of the intervention participants will be determined from a larger list of possible topics, with each group including the following core topics: Impact of Cancer on the Family, Spirituality and Cancer, Stress Management, Balancing Physical and Emotional Needs and Improving Communication.
Study: NCT03120299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Description: Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
Study: NCT00005845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00999141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FS VH S/D 4 s-apr
Description: FS VH S/D 4 s-apr will be applied (using spray device provided by Sponsor) to the subcutaneous plane (intraoperative, topical administration) in both the neck and the face area.
Study: NCT02815137

Intervention type: OTHER
Group type: OTHER
Intervention: Digital Polymerase Chain Reaction
Description: Determination of mutation of XPO1 E571K by digital PCR in blod sample of patient with classical hodgkin lymphoma
Study: NCT02929316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: IV infusion week 0, 2 and 6
Study: NCT02427958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin
Description: Suspension for injection.
Study: NCT00204516

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA coding for melanoma associated antigens
Description: mRNA vaccine s.c. applied weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Given s.c. as adjuvant drug one day after vaccine
Study: NCT00711607

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nomegestrol acetate and estradiol
Description: Group 1: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 and day 35; Group 2: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 followed by one Placebo tablet on day 35
Study: NCT01323504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Patient are listen music during their local care

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: no music
Description: There are no music during the local care
Study: NCT01481519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone 0.1%/povidone-iodine 0.4%
Description: dexamethasone 0.1%/povidone-iodine 0.4%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial Tears
Description: artificial tears 1 drop, 4 times per day
Study: NCT00143741

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin (Lipitor)
Description: 20mg every day, taken by mouth. Dose could be increased up to 60mg every day during the course of the trial if tests indicate this is needed.
Study: NCT04152395

Intervention type: OTHER
Intervention: EVAR
Description: Patients undergoing EVAR

Intervention type: OTHER
Intervention: EVAR
Description: Patients undergoing EVAR
Study: NCT01334762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole/IUI
Description: Patients received 5 mg letrozole daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CC/IUI
Description: Patients received 100 mg lCC daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
Study: NCT03847922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide + Oxygen Gas (Product)
Description: Self-administered 50% nitrous oxide / 50% oxygen mixture will be given to the intervention group, starting just before the beginning of the urethral bulking procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lidocaine gel 2%
Description: 6mL of 2% lidocaine gel will be inserted and injected into the urethral canal approximately 10 minutes prior to the procedure for each participant regardless of group assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine gel 2%
Description: 6mL of 2% lidocaine gel will be inserted and injected into the urethral canal approximately 10 minutes prior to the procedure for each participant regardless of group assignment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Room air
Description: Room air will be administered via the Pro-Nox machine to participants in the control group, starting just before the beginning of the urethral bulking procedure.
Study: NCT03723915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wild-type Reovirus
Description: Given pelareorep IV
Study: NCT04677933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: OLP-1002
Description: 10 patients will receive 5 µg OLP-1002 twice-weekly (BIW) OLP-1002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B: OLP-1002
Description: 10 patients will receive 10 µg OLP-1002 BIW OLP-1002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: Placebo
Description: 10 patients will receive Placebo BIW
Study: NCT01246050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HF training
Description: These are CBOC Providers who received HF Training as the active intervention. HF training includes didactic lectures, case discussions and interactive symposia, course materials including teaching material, textbooks, copies of HF clinical guidelines and patient education material for distribution, participation in HF Clinics and Inpatient Heart Failure Rounds. Providers were given access to clinical pharmacist services Including medication and disease teaching, adjustment and uptitration. There was quarterly analysis of patient compliance including individualized confidential, non-punitive feedback to providers from a set of prespecified core HF performance measures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No HF training
Description: These are control providers drawn from the same CBOCs who have not received HF training, access to clinical pharmacist medication titration services or performance feedback
Study: NCT05742659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A mobile-based interactive simulation scheme (MISS)
Description: A mobile-based interactive simulation scheme (MISS) was proposed and developed to investigate its effects on facilitating hands-on learning of NG insertion in undergraduate medical students.
Study: NCT04113928

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Broccoli & mustard seed soup
Description: 200ml acute feed

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Broccoli & mustard seed soup
Description: 200ml acute feed

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Broccoli soup
Description: 200ml acute feed

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Broccoli soup
Description: 200ml acute feed
Study: NCT00941109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Cohort 1: 30 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Cohort 2: 60 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Cohort 3: 120 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Cohort 4: 240 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
Study: NCT03168490

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten Friendly bread
Description: parallel study

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten Friendly bread
Description: parallel study

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten Friendly bread
Description: parallel study

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gluten Friendly bread
Description: parallel study

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gluten Friendly bread
Description: parallel study
Study: NCT01262924

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine
Description: Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' reduced-antigen-content acellular pertussis vaccine
Description: Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tedivax-Adult™/ Td-Rix™
Description: Intramuscular, single dose or 2 doses (in the annex phase)
Study: NCT03172364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micellar cleanser
Description: Participants will apply the micellar cleanser topically twice a day (morning and evening). Micellar cleanser will be applied on cotton pad and wiped over the entire face and closed eye to gently cleanse. No need to rub or rinse the micellar cleanser.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micellar foaming cleanser
Description: Participants will use the micellar foaming cleanser topically twice a day (morning and evening). Micellar foaming cleanser will be massaged gently onto wet skin on the face using fingertips. After which participants will rinse thoroughly and pat the skin dry.
Study: NCT02362347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: London Health Sciences Centre - Compression Vest
Description: London Health Sciences Centre - Compression Vest

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercise
Study: NCT03023852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: Participants will receive JNJ-63623872 600 mg (2\*300 mg) oral tablets in Panel 1 and 2 under Fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: Participants will receive JNJ-63623872 600 mg (2\*300 mg) oral tablets in Panel 1 and 2 under Fasted conditions.
Study: NCT02791646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training Full
Description: Pain Coping Skills Training Full(PCST-Full) will consist of a 5-session intervention delivered to participants at the medical center by their therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Brief
Description: Pain coping skills training brief (PCST-Brief) will consist of a 60 minute, in-person session followed by 4-weeks of daily text messaging
Study: NCT02954822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin→Evogliptin+Glimepiride→Glimepiride
Description: Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days. After the washout period for 10 days, Glimepiride 4mg will be administered for 2 days.~Glimepiride : Glimepiride 4mg QD~Evogliptin + Glimepiride : Evogliptin 5mg QD + Glimepiride 4mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride→Evogliptin→Evogliptin+Glimepiride
Description: After 2 days of administration of Glimepiride 4mg follows the 10-day washout period. Afterwards Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days.
Study: NCT02155075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIRA device imaging
Description: MIRA device imaging for adjunctive detection of breast cancer. Arm 1 administarte result

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIRA device imaging
Description: MIRA device imaging for adjunctive detection of breast cancer. Arm 1 administarte result
Study: NCT02301039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study: NCT02713854

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial biopsy
Description: An endometrial biopsy taken 2-3 months prior to IVF cycle
Study: NCT00798018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine
Description: lidocaine: 2%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
Study: NCT00798018

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Air injected into the cuff to seal the space between the trachea and the tube at minimal volume

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% tetracaine
Description: tetracaine: 1%, injected into the cuff to seal the space between the trachea and the tube at minimal volume

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N.S
Description: 0.9% Normal saline injected into the cuff to seal the space between the trachea and the tube at minimal volume
Study: NCT02779660

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Description: RIPC will be induced by the application of 3 short episodes (5 minutes) of forearm ischemia by cuff sphygmomanometer inflation separated by 5 minutes of reperfusion.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham-intervention
Description: In the control group the cuff will be inflated for 3 times at 10 mm Hg for 5 minutes with 5-minute intervals
Study: NCT04621838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned interventions.
Description: Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use, with Silicone Foam Dressing and Silicone Foam Lite Dressing.~The patients will be evaluated at each dressing change over a six-week period (per Product) or until the wound is healed to extent that the use of the Silicone Foam and Silicone Foam Lite dressing is no longer indicated from the time that the patient has been recruited.
Study: NCT01054391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEC - Neurovascular Embolization Cover
Description: Implantation of NEC for the treatment of intracranial aneurysms and carotid/vertebrobasilar fistuale arising from a parent vessel of 2.5 to 4.5mm
Study: NCT03630913

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tagged axillary metastatic node
Description: First, initially metastatic lymph node is tagged with a metal clip under sonography. Then, patients receive NAC before surgery.~Breast surgery (conservative or radical) and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC.~SLN isotope detection is performed with or without blue dye. All patients undergo the resection of the tagged axillary node, SLN biopsy and a complementary axillary lymphadenectomy.
Study: NCT01153620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lavasept 0.04%
Description: Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Lavasept® 0.04% 50 ml 50ml or as much needed to completely saturate the compress.~Treatment Duration 60 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ringer's Solution
Description: Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Ringers' solution 50ml or as much needed to completely saturate the compress. Treatment Duration 60 minutes
Study: NCT05248724

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: periarticular infiltration (50ml) with Ropivacaine Hydrochloride 10 MG/ML (200 mg) + ketorolac tromethamine 30 mg/ml (30 mg) + adrenaline 1mg/ml (300 microgram) + morphine hydrochloride 10mg/ml (5 mg)
Description: Patients allocated to the intervention group received a periarticular infiltration with a solution containing 200 mg of ropivacaine hydrochloride ,150 mg if the patient weight was below 65kg, 5 mg of morphine hydrochloride , 30 mg of ketorolac tromethamine, 300 micrograms of adrenaline and saline 0.9% till reaching 50 ml of volume. Half of the solution was injected into the proximal hamstring stump. The surgical team closed the wounds and injected the other half of the intervention into the subcutaneous tissue in the distal wound and portals. There was not any medication introduced inside the articulation. Patients of the placebo group were treated in the same way, but the solution injected was 50 ml of saline 0.9%.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 50 ml of 0.9 saline
Study: NCT02669914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Study: NCT00822224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEOPA
Description: inhalation of MEOPA during the painful care